An expert discusses a treatment approach for the patient case above, how factors like brain metastases influence first-line treatment choices, reviews high-risk/CNS outcomes data from MARIPOSA and ...

An expert discusses treatment goals for patients with EGFR-mutated advanced/metastatic NSCLC, how to approach combination therapy with high-risk patients, and how recent data has influenced their ...

Innovent Biologics presents data from phase 1 PoC study of IBI363 to treat advanced NSCLC at 2025 ASCO: San Francisco Friday, June 6, 2025, 18:00 Hrs [IST] Innovent Biologics, Inc ...

AbbVie’s telisotuzumab adizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this ...

Here is a recap of every FDA approval announced by the regulatory agency in the month of May, spanning various cancer types.

Manmeet Ahluwalia, MD, MBA, FASCO, chief of medical oncology, chief scientific officer, and deputy director of the Miami ...

Results from three trials continue to demonstrate the potential of DATROWAY® (datopotamab deruxtecan) in combination with ...

The MHRA has approved aumolertinib for adult patients with non-small cell lung cancer (NSCLC), following a groundbreaking ...

Despite its success in advanced melanoma, Bristol Myers Squibb’s fixed-dose PD-1/LAG-3 combo, Opdualag, failed to move the ...

RxDx assay as a companion diagnostic to identify c-Met protein expression in non-squamous NSCLC patients eligible for treatment with Emrelis.

UK MHRA approves SFL Pharmaceuticals’ aumolertinib to treat non-small cell lung cancer: United Kingdom Wednesday, June 4, 2025, 11:00 Hrs [IST] The Medicines and Healthcare prod ...

The leading PD-1+ NSCLC Companies such as Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan Biotechnology, Genor Biopharma and others. Promising PD-1+ ...